Background: There are no existing high-volume studies characterizing human papillomavirus (HPV)-associated nasopharyngeal cancer (NPC).
poorly characterized, being limited to the aforementioned small-volume series. Therefore, it is difficult to ascertain clinical factors associated with HPV-positive versus HPVnegative disease. Moreover, as a result of small-volume reports, there are conflicting data as to whether or not HPV is associated with an improved prognosis in NPC. [9] [10] [11] [12] [13] [14] [15] Indeed, as the focus of HPV-induced OPC enters the realm of phase III trials that could change clinical management, it is becoming increasingly critical to address with largevolume investigations whether there are links between HPV and prognoses in other head and neck neoplasms.
The National Cancer Data Base (NCDB) provides a unique resource with which to address these novel and clinically important issues in a relatively uncommon population. This is the largest study to date evaluating HPV status in NPC; we sought to identify clinical factors associated with HPV-positive disease and assess overall survival (OS) in HPV-positive versus HPV-negative cohorts.
| M ATE RI ALS AN D ME THO DS
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society, which consists of deidentified information regarding tumor characteristics, patient demographics, and patient survival for approximately 70% of the U.S. population. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] The NCDB contains information not included in the Surveillance, Epidemiology, and End Results database, including details regarding use of systemic therapy and the dose of radiotherapy (RT). The data used in the study were derived from the deidentified NCDB NPC file (there were no other subsite files utilized). By definition, the primary site in each patient in this file is coded to be in the nasopharynx (International Classification of Disease-O-3 code C11). The American College of Surgeons and the Commission on Cancer have not verified and are neither responsible for the analytic or statistical methodology used nor the conclusions drawn from these data by the investigators. As all patient information in the NCDB database is deidentified, this study was exempt from institutional review board evaluation and informed consent. Inclusion criteria for this study were patients with histologically confirmed NPC with known HPV status. In the NCDB, HPV-positivity refers to high-risk type 16 and/or 18 using assays of in situ hybridization and/or immunohistochemical p16 expression. 32 Patients receiving any form of pharyngectomy (or surgery not otherwise specified) were excluded, as were patients with incomplete information on staging or RT. Patients with singular elements of missing TNM or overall staging were included as long as the remainder were present. Other exclusion criteria were benign histology or palliative care treatment. In accordance with the variables in NCDB files, information collected on each patient broadly included demographic, clinical, and treatment data. All statistical tests were performed with SAS software (version 9.4; SAS Institute, Cary, NC); tests were 2-sided, with a threshold of P < .05 for statistical significance. Univariate and multivariate logistic regression was used to determine characteristics associated with patients with HPVpositive disease. All initially examined variables were considered for inclusion into models for stepwise selection. Next, survival analysis (performed using Kaplan-Meier methodology) evaluated OS, defined as the interval between the date of diagnosis and the date of death, or censored at last contact. Subsequently, Cox proportional hazards modeling was utilized to evaluate predictors of OS; the proportional hazards assumptions in the Cox models were met. Last, owing to the inclusivity of the initial patient population, a secondary survival analysis was performed based on excluding nonuniform presentation and treatment, followed by additional exclusion for patients not receiving chemotherapy or RT to a RT dose of 66 Gy per national guidelines 33 and those with M1 disease additionally.
After exclusion, the remaining population underwent propensity matching analysis; OS between the matched cohorts was then evaluated. Propensity matching creates quasicase/ control pairs using a retrospective cohort in efforts to account for both recorded and unrecorded confounding variables. 34 Propensity scores were calculated by use of a multivariable logistic regression model with the dependent variable as HPV status and the independent variables based on those found significant on the univariate analysis. One-to-one matching was done so as to avoid potential bias from manyto-one matching. Furthermore, in order to ensure balance of the covariates within the 2 cohorts, standardized differences were assessed with the value <0.1, signifying an inconsequential imbalance. 35, 36 
| RES U LTS
A complete flow diagram of patient selection is provided in Figure 1 . In total, 956 patients met study analysis criteria; this included 308 patients (32%) with HPV-positive disease and 648 patients (68%) who were HPV-negative. Table 1 displays notable clinical characteristics of the analyzed patients as stratified for HPV status. The majority of patients were white, men, and living in metropolitan areas. Of note, the number of HPV-positive NPC diagnoses has steadily risen since first recorded in the NCDB in 2009, as in this dataset (see Figure 2 ). After univariate analysis was performed to assess for factors associated with positive HPV status, multivariate analysis revealed several independent factors associated with HPV-positive disease. These patients were less likely to be uninsured/unknown insurance status (P 5 .003), and more likely to live in zip codes with lower high school graduation rates (P < .05). Although there was no association with age on univariate analysis, patients with HPV-positive disease were independently younger on multivariate analysis (odds ratio 0.974; P 5 .008). HPV-positive NPC tended to present more frequently with more advanced T classification (P < .05), but HPV status did not correlate with N classification, M classification, or overall stage (P > .05 for all). Although HPV-positive and HPV-negative tumors received similar RT doses, HPV-positive cases were independently less likely to receive chemotherapy (P 5 .006).
Median follow-up was 23 months (range 0-67 months). Kaplan-Meier estimates comparing OS in HPV-positive and HPV-negative cohorts are illustrated in Figure 3A . The 3-year OS in the respective groups were 79% and 63% (P 5 .171). This corresponded to median OS of 50 months (95% confidence interval [CI], 40 months-not reached) versus 43 months (95% CI 38-48 months), respectively.
In the overall cohort, there were several predictors of OS on univariate and multivariate analysis ( Table 2 ). Among others, independent predictors of poor OS included increasing age (P 5 0.004) and later diagnosis year of 2011-2013 (P < .001). Of note, there did not seem to be independent associations with advanced T classification, nor with N classification and overall stage (P > .05), nor the receipt of chemotherapy (P 5 .788). The HPV status did not predict for OS on either univariate (P 5 .120) or multivariate (P 5 .183) analyses.
After excluding patients with M1 disease and patients who did not receive standard of care therapy with chemotherapy and RT to a dose of 66 Gy, the remainder of the population was propensity matched. propensity-matched cohorts were well-balanced in each variable. The OS was not significantly different between the matched populations, corresponding to 3-year OS of 76% for HPV-positive and 77% for HPV-negative cases ( Figure 3B ; P 5 .734).
| D IS C US S I ON
HPV-positive NPC diagnoses have steadily risen over the past several years, and thus it is becoming increasingly essential to provide high-volume studies evaluating unresolved questions regarding patient characterization and prognosis. Our study of a large national database, which we believe to be the largest report assessing HPV status in NPC to date, most notably characterizes sociodemographic factors associated with HPV-positive NPC. Our findings support a lack of association of HPV status on OS in NPC. Based on our analysis, as compared with HPV-positive OPC, 1,2 HPV-positive NPC occurs in somewhat similar sociodemographic groups -younger, living in more educated areas, and less often being uninsured. However, this condition is also associated with more advanced T classification. Notably, the NCDB does not assess smoking status, and to this extent further evaluation with institutional data is needed. Despite similar RT doses in both groups, it is unknown why HPV-positive NPC was less likely to receive chemotherapy, but factors not provided by the NCDB (eg, performance status) and individualized decision making of administering chemotherapy to T1N0 and select T2N0 cases may play a role. Last, there was also a trend toward fewer patients identified as "other" for race (mostly consisting of several Asian subethnicities) that were HPV-negative, which is consistent with existing series as well as notions of Asians tending to have EBV-related disease. 8 The most notable finding of our high-volume investigation, in response to aforementioned conflicting studies, was that there were no appreciable differences in OS between HPV-positive and HPV-negative cohorts, which were supported both by multivariate analysis and propensity matching. Although several factors previously reported to predict for OS were not found to do so on multivariate analysis (eg, stage or chemotherapy use), it is important to recognize that this population exhibits a specifically selected cohort that likely does not represent all patients with NPC. This is exemplified by nearly one-third of patients in this cohort being HPV-positive, even though the overall incidence of HPVpositive NPC is very likely to be much lower. This could be related to differing sensitivities and specificities of various assays that measure HPV status, along with thresholds for delineating a binary definition of "positivity" in these assays. Additionally, although the patients in this dataset were all coded with a primary site corresponding to the nasopharynx, extension to the oropharynx (and if so, to what degree) is unknown and a shortcoming of the coding in the NCDB. Nevertheless, these results raise the question of whether it is worth routinely evaluating HPV in patients with NPC, an issue that has not been addressed heretofore by national recommendations. 33 Moreover, Wilson and colleagues 11 suggested that p16 testing had a positive predictive value of just 67% in NPC, albeit with just 13 NPC cases, but other methods may improve detectability. 37 Nevertheless, although we are limited in that the NCDB does not describe the method of HPV evaluation, our data do not support a role for routine HPV testing in NPC for prognostic or management purposes. Because a major limitation of the NCDB is a lack of recording EBV and World Health Organization status, it would also be important for future high-volume studies to assess survival outcomes in patients with NPC with various combinations of HPV and EBV status. A series of 61 patients suggested that EBV-positive disease has better outcomes than HPV-positive and EBV-negative/HPV-negative cases, 12 but such analyses are prone to distortion from lower sample sizes, selection bias, and regional/nation-related biases (limiting generalizability to Asian countries, for instance). Although some investigations have implied that EBV and HPV positivity is mutually exclusive, 4,7,9 others have observed the opposite. 15 Nevertheless, as more such cases are expected to be diagnosed in the future, further data are required.
Although the NCDB provides a unique platform with which to study this important clinical question, this investigation is not without important limitations. First, the NCDB studies are inherently retrospective with shorter follow-up times, they have potential for miscoding, and it is possible that some oropharyngeal cancers with nasopharyngeal extension were miscoded and included in this analysis. The shorter follow-up time in a neoplasm with relatively prolonged survival is also an acknowledged shortcoming. Second, the NCDB does not keep track of precise reasons for HPV testing, and, hence, there may be selection bias as compared to the "general" NPC population (including limited applicability to other countries in which NPC is endemic). Nevertheless, it may be interesting to examine factors associated with undergoing HPV testing versus lack thereof. Third, the NCDB does not record outcomes other than OS, and, thus, the effect of HPV status on other end points, such as cancerspecific survival and locoregional control cannot be addressed. Furthermore, the NCDB does not allow for an assessment of subsequent lines of treatment (eg, reirradiation, further systemic therapy, and/or targeted therapy), which could influence OS (although the benefit of adjuvant chemotherapy in NPC is controversial). 38 Fourth, although propensity-matching techniques were utilized herein to reduce potential biases, the matched population had a relatively smaller sample size. Last, the NCDB does not provide details, such as RT field design/volumes/techniques or specific chemotherapy type that may influence outcomes.
| CON CLU S IO NS
Using the NCDB, we believe that this is the largest study to date evaluating HPV status in NPC. Sociodemographic factors associated with HPV-positive disease are first presented. The HPV-positive disease presented with more advanced T classification, but not N classification or grouped stage. In both the overall and matched cohorts, there were no differences in OS between HPV-positive and HPV-negative patients, and HPV status did not independently predict for OS. Owing to the difficulty of addressing causality in database studies, further work must corroborate the findings herein.
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